<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-PCV-2843</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2843</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Провоспалительные цитокины VEGFA, IL-6, IL-8 как маркеры гепатотоксичности после COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Proinflammatory cytokines VEGFA, IL-6, IL-8 as markers of hepatotoxicity after COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6919-8666</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уревский</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Urevskii</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Уревский М.А. – студент медицинского факультета Института медицины, экологии и физической культуры, стажер-исследователь Научноисследовательского технологического института имени С.П. Капицы </p><p>г. Ульяновск</p></bio><bio xml:lang="en"><p>Urevskii M.A., Student, Faculty of Medicine, Institute of Medicine, Ecology, and Physical Education, Research Intern at the S. Kapitza Technological Research Institute </p><p>Ulyanovsk</p></bio><email xlink:type="simple">mark.urevskiy@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8472-2550</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ильмухина</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ilmukhina</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ильмухина Л.В. – к.м.н., доцент кафедры дерматовенерологии и инфекционных болезней медицинского факультета Института медицины, экологии и физической культуры  </p><p>г. Ульяновск</p></bio><bio xml:lang="en"><p>Ilmukhina L.V., PhD (Medicine), Associate Professor, Department of Dermatovenerology and Infectious Diseases, Faculty of Medicine, Institute of Medicine, Ecology, and Physical Education </p><p>Ulyanovsk</p></bio><email xlink:type="simple">ilmuhin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8498-9554</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саранская</surname><given-names>Я. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Saranskaya</surname><given-names>Ya. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Саранская Я.Е. – старший преподаватель кафедры дерматовенерологии и инфекционных болезней медицинского факультета Института медицины, экологии и физической культуры  </p><p>г. Ульяновск</p></bio><bio xml:lang="en"><p>Saranskaya Ya.E., Senior Lecturer, Department of Dermatovenerology and Infectious Diseases, Faculty of Medicine, Institute of Medicine, Ecology, and Physical Education </p><p>Ulyanovsk</p></bio><email xlink:type="simple">ms.saranskaya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-0545-5679</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лапшин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lapshin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лапшин А.А. – студент медицинского факультета Института медицины, экологии и физической культуры </p><p>г. Ульяновск</p></bio><bio xml:lang="en"><p>Lapshin A.A., Student, Faculty of Medicine, Institute of Medicine, Ecology, and a medical student at the Institute of Medicine, Ecology, and Physical Education </p><p>Ulyanovsk</p></bio><email xlink:type="simple">artem.lapshin.99@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-8353-5192</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гафурова</surname><given-names>Р. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Gafurova</surname><given-names>R. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гафурова Р.Р. – студентка медицинского факультета Института медицины, экологии и физической культуры </p><p>г. Ульяновск</p></bio><bio xml:lang="en"><p>Gafurova R.R., Student, Faculty of Medicine, Institute of Medicine, Ecology, and a medical student at the Institute of Medicine, Ecology, and Physical Education </p><p>Ulyanovsk</p></bio><email xlink:type="simple">regina.gafurova.99@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ульяновский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ulyanovsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><fpage>803</fpage><lpage>808</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Уревский М.А., Ильмухина Л.В., Саранская Я.Е., Лапшин А.А., Гафурова Р.Р., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Уревский М.А., Ильмухина Л.В., Саранская Я.Е., Лапшин А.А., Гафурова Р.Р.</copyright-holder><copyright-holder xml:lang="en">Urevskii M.A., Ilmukhina L.V., Saranskaya Y.E., Lapshin A.A., Gafurova R.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2843">https://www.mimmun.ru/mimmun/article/view/2843</self-uri><abstract><p>Механизм гепатоцелюллярного повреждения печени после COVID-19 – многофакторный процесс. В литературе наиболее обсуждаемыми причинами являются прямые цитолитические повреждения печени вследствие воспалительной реакции после COVID-19, лекарственно индуцированной гепатотоксичности и прямого цитотоксического действия вируса. Существуют наблюдения, что инфекция SARS-CoV-2 вызывает реактивацию вируса гепатита В, однако взаимодействие между вирусом гепатита С и SARS-CoV-2 описано мало. Течение коронавирусной инфекции связано с выраженной экcпрессией провоспалительных цитокинов – участников мультисистемного воспалительного ответа – IL-1β, IL-6, IL-8, IL-18, MCP-1, TNFα, что вносит существенный вклад в наблюдаемые ранние и поздние нарушения функции печени. Цель исследования – оценить роль провоспалительных цитокинов (VEGFA, IL-8, IL-6, MCP-1, TNFα, IL-18) как дополнительных маркеров гепатотоксичности после COVID-19. Исследование выполнено в период с марта по август 2022 года на базе поликлиики № 2 ЦК МСЧ г. Ульяновска. Пациенты были разделены на 2 группы: 1-я группа – с повышением аминотрансфераз на фоне лечения от COVID-19 и/или в последующие 3-6 месяцев после перенесенного заболевания без вирусного поражения печени (n = 42), 2-я группа – пациенты с ко-инфекцией (хроническим вирусным гепатитом С (HCV) и COVID-19 (n = 26). Методом иммуноферментного анализа оценивались уровни цитокинов – VEGF-A, IL-6, IL-8, MCP-1, IL-18, TNFα в сыворотке крови. Статистический анализ проводился с использованием программы StatTech v.3.1.4. Выявлено сопоставимое повышение уровня трансаминаз и С-реактивного белка в обоих группах, значимо отличающееся от референсных значений. Установлены прямые корреляционные связи умеренной силы (линейная корреляция по Спирмену) между следующими цитокинами: TNFα-MCP-1 (R = 0,559; p = 0,001), TNFα-VEGFA (R = 0,400; p = 0,002), TNFα-IL-6 (R = 0,503; p = 0,001). Нами установлено значимое повышение уровня VEGFA в сыворотке крови пациентов 1-й группы (гепатотоксичность после COVID-19) (Me (Q0,25-Q0,75): 522 (250-1002), p = 0,001) и у пациентов 2-й группы (HCV + COVID-19) (Me 1196, Q0,25-Q0,75: (73-432). Аналогичная тенденция наблюдается с сывороточными уровнями IL-6 и IL-8 в 1-й группе пациентов, выражено превышающими значения цитокинов у здоровых доноров и достоверно выше, чем у пациентов 2-й группы. Выявленные корреляционные связи между воспалительными цитокинами доказывают однонаправленность изменений в функционирований регуляторной сети, контролирующей иммунные вирус-индуцированные реакции.</p></abstract><trans-abstract xml:lang="en"><p>The mechanism of hepatocellular liver damage after COVID-19 is a multifactorial process. The most widely discussed causes are cytolytic liver damage due to the inflammatory response after COVID-19, drug-induced hepatotoxicity and direct cytotoxic effect of the virus. There are observations that SARSCoV-2 infection causes hepatitis B virus reactivation, but little has been described about the interaction between hepatitis C virus and SARS-CoV-2. The course of coronavirus infection is associated with marked expression of proinflammatory cytokines, participants in the multisystem inflammatory response, IL-1β, IL-6, IL-8, IL-18, MCP-1, TNFα, which contribute significantly to the observed early and late liver function impairment. The aim of the study was to evaluate the role of proinflammatory cytokines (VEGFA, IL-8, IL-6, MCP-1, TNFα, IL-18) as additional markers of hepatotoxicity after COVID-19. The study was performed between March and August 2022. Patients were divided into 2 groups: Group 1 – with increased aminotransferases against the background of treatment from COVID-19 and/or in the following 3-6 months after the disease without viral liver damage (n = 42), Group 2 – patients with co-infection (chronic viral hepatitis C (HCV) and COVID-19 (n = 26). The levels of cytokines – VEGF-A, IL-6, IL-8, MCP-1, IL-18, TNFα in blood serum were estimated by enzyme immunoassay method. Statistical analysis was performed using StatTech v. 3.1.4. The results of the study revealed a comparable increase in the level of transaminases and C-reactive protein in both groups, significantly different from the reference values. Direct correlations of moderate strength (linear Spearman correlation) were found between the following cytokines: TNFα-MCP-1 (R = 0.559; p = 0.001), TNFα-VEGFA (R = 0.400; p = 0.002), TNFα-IL-6 (R = 0.503; p = 0.001). We diagnosed a significant increase in serum VEGFA levels in group 1 patients (hepatotoxicity after COVID-19) (Me (Q0.25-Q0.75): 522 (250 to 1002), p = 0.001) and in group 2 patients (HCV + COVID-19) (Me 1196, Q0.25-Q0.75: (73 to 432). Similar trend with the level of IL-6, IL-8, exceeding the values of cytokines in healthy donors and significantly higher than in group 2 patients. Identified correlations between inflammatory cytokines prove unidirectional changes in the functioning of the regulatory network controlling immune virus-induced reactions.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гепатотоксичность</kwd><kwd>COVID-19</kwd><kwd>воспалительные маркеры</kwd><kwd>васкулоэндотелиальный фактор роста</kwd><kwd>IL-6</kwd><kwd>IL-8</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepatotoxicity</kwd><kwd>COVID-19</kwd><kwd>inflammatory markers</kwd><kwd>vascular endothelial growth factor</kwd><kwd>IL-6</kwd><kwd>IL-8</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Alqahtani S.A., Schattenberg J.M. Liver injury in COVID-19: The current evidence. United European Gastroenterol J., 2020, Vol. 8, no. 5, pp. 509-519.</mixed-citation><mixed-citation xml:lang="en">Alqahtani S.A., Schattenberg J.M. Liver injury in COVID-19: The current evidence. United European Gastroenterol J., 2020, Vol. 8, no. 5, pp. 509-519.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bzeizi K., Abdulla M., Mohammed N., Alqamish J., Jamshidi N., Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci. Rep., 2021, Vol. 11, no. 1, 10599. doi: 10.1038/s41598-021-89513-9.</mixed-citation><mixed-citation xml:lang="en">Bzeizi K., Abdulla M., Mohammed N., Alqamish J., Jamshidi N., Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci. Rep., 2021, Vol. 11, no. 1, 10599. doi: 10.1038/s41598-021-89513-9.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cabibbo G., Rizzo G.E.M., Stornello C., Craxì A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J. Viral Hepat., 2021, Vol. 28, no. 1, pp. 4-11.</mixed-citation><mixed-citation xml:lang="en">Cabibbo G., Rizzo G.E.M., Stornello C., Craxì A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J. Viral Hepat., 2021, Vol. 28, no. 1, pp. 4-11.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. Exploration (Beijing), 2021, Vol. 1, no. 2, 20210051. doi: 10.1002/EXP.20210051.</mixed-citation><mixed-citation xml:lang="en">Cao Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. Exploration (Beijing), 2021, Vol. 1, no. 2, 20210051. doi: 10.1002/EXP.20210051.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Devaux C.A., Lagier J.C. Unraveling the underlying molecular mechanism of ‘Silent Hypoxia’ in COVID-19 patients suggests a central role for angiotensin II modulation of the AT1R-hypoxia-inducible factor signaling pathway. J. Clin. Med., 2023, Vol. 12, no. 6, 2445. doi: 10.3390/jcm12062445.</mixed-citation><mixed-citation xml:lang="en">Devaux C.A., Lagier J.C. Unraveling the underlying molecular mechanism of ‘Silent Hypoxia’ in COVID-19 patients suggests a central role for angiotensin II modulation of the AT1R-hypoxia-inducible factor signaling pathway. J. Clin. Med., 2023, Vol. 12, no. 6, 2445. doi: 10.3390/jcm12062445.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dufour J.F., Marjot T., Becchetti C., Tilg H. COVID-19 and liver disease. Gut, 2022, Vol. 71, no. 11, pp. 2350-2362.</mixed-citation><mixed-citation xml:lang="en">Dufour J.F., Marjot T., Becchetti C., Tilg H. COVID-19 and liver disease. Gut, 2022, Vol. 71, no. 11, pp. 2350-2362.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kruse R.L. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res., 2020, Vol. 9, 72. doi: 10.12688/f1000research.22211.2.</mixed-citation><mixed-citation xml:lang="en">Kruse R.L. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res., 2020, Vol. 9, 72. doi: 10.12688/f1000research.22211.2.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lu X.H., Yang J.L., Deng K. COVID-19 Patients With Hepatitis B Virus Infection. Am. J. Gastroenterol., 2021, Vol. 116, no. 6, pp. 1357-1358.</mixed-citation><mixed-citation xml:lang="en">Lu X.H., Yang J.L., Deng K. COVID-19 Patients With Hepatitis B Virus Infection. Am. J. Gastroenterol., 2021, Vol. 116, no. 6, pp. 1357-1358.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J. Clin. Cases, 2022, Vol. 10, no. 4, pp. 1140-1163.</mixed-citation><mixed-citation xml:lang="en">Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J. Clin. Cases, 2022, Vol. 10, no. 4, pp. 1140-1163.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sodeifian F., Seyedalhosseini Z.S., Kian N., Eftekhari M., Najari S., Mirsaeidi M., Farsi Y., Nasiri M.J. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front. Med. (Lausanne), 2021, Vol. 8, 731436. doi: 10.3389/fmed.2021.731436.</mixed-citation><mixed-citation xml:lang="en">Sodeifian F., Seyedalhosseini Z.S., Kian N., Eftekhari M., Najari S., Mirsaeidi M., Farsi Y., Nasiri M.J. DrugInduced Liver Injury in COVID-19 Patients: A Systematic Review. Front. Med. (Lausanne), 2021, Vol. 8, 731436. doi: 10.3389/fmed.2021.731436.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wong G.L., Wong V.W., Thompson A., Jia J., Hou J., Lesmana C.R.A., Susilo A., Tanaka Y., Chan W.K., Gane E., Ong-Go A.K., Lim S.G., Ahn S.H., Yu M.L., Piratvisuth T., Chan H.L.; Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol. Hepatol., 2020, Vol. 5, no. 8, pp. 776-787.</mixed-citation><mixed-citation xml:lang="en">Wong G.L., Wong V.W., Thompson A., Jia J., Hou J., Lesmana C.R.A., Susilo A., Tanaka Y., Chan W.K., Gane E., Ong-Go A.K., Lim S.G., Ahn S.H., Yu M.L., Piratvisuth T., Chan H.L.; Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol. Hepatol., 2020, Vol. 5, no. 8, pp. 776-787.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
